# Direclidine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/direclidine

> The next catalyst for direclidine, sponsored by NEUROCRINE BIOSCIENCES INC (NBIX), is its interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for direclidine?

The next catalyst for direclidine, sponsored by NEUROCRINE BIOSCIENCES INC (NBIX), is its interim data readout, 2027. SEC Form 10-K: "We have initiated a comprehensive Phase 3 clinical program for direclidine in schizophrenia (with initial topline data expected in 2027), including studies evaluating efficacy in patients experiencing an acute relapse of schizophrenia and long-term safety." [Calendar and source filings](https://sec-api.dev/pdufa/direclidine)

Source: SEC Form 10-K, accession 0000914475-26-000007, https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-02-11. Cite: https://sec-api.dev/pdufa/direclidine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | direclidine |
| Codes | NBI-1117568 |
| Sponsor | NEUROCRINE BIOSCIENCES INC (NBIX) https://sec-api.dev/companies/nbix/catalysts |
| Indications | [schizophrenia](https://sec-api.dev/indications/schizophrenia) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: schizophrenia.
- First seen 2025-02-10, last confirmed 2025-02-10.
- SEC Form 10-K (accession 0000914475-25-000037): "In August 2024, we announced positive top-line data from the Phase 2 clinical study of NBI-1117568 in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-10, last confirmed 2025-02-10.
- SEC Form 10-K (accession 0000914475-25-000037): "We expect to advance NBI-1117568 into Phase 3 development in the first half of 2025, which would trigger an additional $15.0 million milestone payment to Nxera upon initiation of the Phase 3 study." https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm
- SEC Form 10-K (accession 0000914475-25-000037): "We expect to advance NBI-1117568 into Phase 3 development in the first half of 2025, which would trigger a milestone of $15.0 million payable to Nxera upon initiation of the Phase 3 clinical study." https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm

### 2027: interim data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-02-11, last confirmed 2026-02-11.
- SEC Form 10-K (accession 0000914475-26-000007): "We have initiated a comprehensive Phase 3 clinical program for direclidine in schizophrenia (with initial topline data expected in 2027), including studies evaluating efficacy in patients experiencing an acute relapse of schizophrenia and long-term safety." https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm

## Same indication

- [Brilaroxazine](https://sec-api.dev/pdufa/brilaroxazine) (RVPH)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/direclidine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Direclidine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/direclidine

```bibtex
@misc{secapidev_pdufa_direclidine_20261116,
  title        = {Direclidine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/direclidine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_direclidine_20261116","title":"Direclidine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/direclidine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
